Oxurion nv enters into a capital commitment of up to €30 million with negma group

Leuven, be, boston, ma, us – april 6, 2021 – 7.30 am cet – oxurion nv (euronext brussels: oxur), a biopharmaceutical company developing next generation standard-of-care back of the eye therapies, today announces that is has agreed to a capital commitment of up to €30 million with negma group.

BCYC Ratings Summary

BCYC Quant Ranking